885595-15-3

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(4-chlorophenyl)-4-[4-[9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl]phen yl]-, 1,1-dimethylethyl ester
• CAS NO: 885595-15-3
• Molecular Formula: C32H36ClN5O3
• Molecular Weight: 574.123
• Mol File: 885595-15-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(4-chlorophenyl)-4-[4-[9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl]phen yl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(4-chlorophenyl)-4-[4-[9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl]phen yl]-, 1,1-dimethylethyl ester(885595-15-3)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(4-chlorophenyl)-4-[4-[9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl]phen yl]-, 1,1-dimethylethyl ester(885595-15-3)

Safety Data

• Hazardous Substances Data: 885595-15-3(Hazardous Substances Data)

Upstream product

• 885595-12-0 4-(1-(tert-butoxycarbonyl)-4-(4-chlorophenyl)piperidin-4-yl)phenylboronic acid 
• 7306-68-5 6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 857531-97-6 4-(4-bromophenyl)-4-(4-chlorophenyl)-piperidine hydrochloride 
• 857532-23-1 tert-butyl 4-(4-bromophenyl)-4-(4-chlorophenyl)piperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 857531-01-2 4-(4-bromo-phenyl)-4-(4-chloro-phenyl)-piperidine 
• 108-90-7 chlorobenzene 
• 57988-58-6 4-(4-bromophenyl)-4-hydroxy-piperidine 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS

The invention provides a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N=C(R6), (R7)C=N, (R8)N-C(O), (R8)2C-C(O), N=N or (R7)C=C(R6); A is an optionally substituted saturated C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, one of the carbon atoms in the linker group being optionally replaced by oxygen or nitrogen; E is a monocyclic or bicyclic carbocyclic or heterocyclic group or an acyclic group X-G wherein X is CH2, O, S or NH and G is a C1-4 alkylene chain wherein one of the carbon atoms is optionally replaced by O, S or NH; R1 is hydrogen or an aryl or heteroaryl group; R2 and R3 are each hydrogen, optionally substituted C1-4 hydrocarbyl or optionally substituted C1-4 acyl; or NR2R3 forms an imidazole group or a saturated monocyclic heterocyclic group having 4-7 ring members; or NR2R3 and A together form a saturated monocyclic heterocyclic group having 4-7 ring members which is optionally substituted by C1-4 alkyl; or NR2R3 and the adjacent carbon atom of linker group A together form a cyano group; or R1, A and NR2R3 together form a cyano group; and R4, R5, R6, R7 and R8 are each independently selected from hydrogen and various substituents as defined in the claims, wherein the compound is for use in: (a) the treatment or prophylaxis of a disease or condition in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated; and/or (b) the treatment of a subject or patient population in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated.

ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS

The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase B, the compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N=C(R6), (R7)C=N, (R8)N-C(O), (R8)2C-C(O), N=N or (R7)C=C(R6); A is an optionally substituted saturated C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, one of the carbon atoms in the linker group being optionally replaced by oxygen or nitrogen; E is a monocyclic or bicyclic carbocyclic or heterocyclic group or an acyclic group X-G wherein X is CH2, O, S or NH and G is a C1-4 alkylene chain wherein one of the carbon atoms is optionally replaced by O, S or NH; R1 is hydrogen or an aryl or heteroaryl group; R2 and R3 are each hydrogen, optionally substituted C1-4 hydrocarbyl or optionally substituted C1-4 acyl; or NR2R3 forms an imidazole group or a saturated monocyclic heterocyclic group having 4-7 ring members; or NR2R3 and A together form a saturated monocyclic heterocyclic group having 4-7 ring members which is optionally substituted by C1-4alkyl; or NR2R3 and the adjacent carbon atom of linker group A together form a cyano group; or R1, A and NR2R3 together form a cyano group; and R4, R5, R6, R7 and R8 are each independently selected from hydrogen and various substituents as defined in the claims.